Why Is SAREPTA THERAPEUTICS (SRPT) Stock Moving Today?

Sarepta Therapeutics (SRPT) stock is moving higher in early trading after the company announced the appointment of Michael Severino, M.D., as its new CEO, effective July 28, 2026. The stock opened with a 2% gap up and traded as high as $16.80 before settling at $16.35 in premarket activity. The leadership change is expected to bring deep industry experience from Severino’s prior roles at AbbVie and Tessera Therapeutics.

What Happened

Sarepta Therapeutics has named Michael Severino as its new CEO, succeeding Doug Ingram. Severino brings a background in biotechnology and drug development, which the company says will support its ongoing expansion and innovation. The transition is part of a broader strategic shift, with the company emphasizing continued growth in its therapeutic portfolio. The news was reported by multiple sources, including MarketChameleon, Seeking Alpha, and StockTitan, all highlighting the significance of the leadership change. Piper Sandler recently lowered its price target for the stock to $20, while Wolfe Research upgraded it to Outperform with a $27 price target.

What The Data Shows

The stock opened at $16.00, a 2.0% increase from the previous close. It reached a session high of $16.80 before settling at $16.35 with a volume of 0.1 million shares, which is 0.0 times the 3-month average. Sarepta has a market cap of $1.7 billion and a P/E ratio of 24.6, with a 52-week range of $10.41 to $25.32. The stock has seen mixed sentiment recently, with a 30-day average of 58/100 and a 7-day average of 54/100.

What To Watch

Investors should monitor the company’s progress toward FDA approval for its Duchenne Muscular Dystrophy drugs, including the PDUFA target date of February 28, 2027. Coverage breadth and analyst reactions will also be key indicators of market confidence in the leadership transition.